Dinaciclib is a potent inhibitor of CDK12 and disrupts homologous recombination Residual HR is a cause of de novo PARP inhibitor resistance in BRCA-mutated cancer Dinaciclib sensitizes resistant BRCA-mutated breast cancer models to PARP inhibition In HR-deficient cancer, dinaciclib augments the response afforded by PARP inhibition